These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 24649896)

  • 1. Utility of immune monitoring in heart transplant recipients on everolimus-based immune suppression.
    Ben Gal T; Israeli M; Yaari V; Hasdai D; Matz I; Yussim A; Battler A; Klein T; Medalion B
    Clin Transplant; 2014 Apr; 28(4):428-33. PubMed ID: 24649896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Benefit of immune monitoring in heart transplant patients using ATP production in activated lymphocytes.
    Kobashigawa JA; Kiyosaki KK; Patel JK; Kittleson MM; Kubak BM; Davis SN; Kawano MA; Ardehali AA
    J Heart Lung Transplant; 2010 May; 29(5):504-8. PubMed ID: 20133166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Individualized immune monitoring of cardiac transplant recipients by noninvasive longitudinal cellular immunity tests.
    Israeli M; Ben-Gal T; Yaari V; Valdman A; Matz I; Medalion B; Battler A; Sredni B; Kristt D; Klein T
    Transplantation; 2010 Apr; 89(8):968-76. PubMed ID: 20075792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benefit of early conversion from CNI-based to everolimus-based immunosuppression in heart transplantation.
    Gude E; Gullestad L; Arora S; Simonsen S; Hoel I; Hartmann A; Holdaas H; Fiane AE; Geiran OR; Andreassen AK
    J Heart Lung Transplant; 2010 Jun; 29(6):641-7. PubMed ID: 20304681
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Everolimus in clinical practice in long-term liver transplantation: an observational study.
    Casanovas T; Argudo A; Peña-Cala MC
    Transplant Proc; 2011; 43(6):2216-9. PubMed ID: 21839237
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Late acute cardiac allograft rejection: new therapeutic options?
    Schweiger M; Wasler A; Prenner G; Tripolt M; Schwarz M; Tscheliessnigg KH
    Transplant Proc; 2005 Dec; 37(10):4528-31. PubMed ID: 16387161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of sirolimus and everolimus in their effects on blood lipid profiles and haematological parameters in heart transplant recipients.
    Tenderich G; Fuchs U; Zittermann A; Muckelbauer R; Berthold HK; Koerfer R
    Clin Transplant; 2007; 21(4):536-43. PubMed ID: 17645716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of everolimus with calcineurin inhibitor medication resulted in post-transplant haemolytic uraemic syndrome in lung transplant recipients--a case series.
    Lovric S; Kielstein JT; Kayser D; Bröcker V; Becker JU; Hiss M; Schiffer M; Sommerwerck U; Haller H; Strüber M; Welte T; Gottlieb J
    Nephrol Dial Transplant; 2011 Sep; 26(9):3032-8. PubMed ID: 21310739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Everolimus and reduced cyclosporine trough levels in maintenance heart transplant recipients.
    Schweiger M; Wasler A; Prenner G; Stiegler P; Stadlbauer V; Schwarz M; Tscheliessnigg K
    Transpl Immunol; 2006 Jun; 16(1):46-51. PubMed ID: 16701176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Everolimus with reduced-dose cyclosporine versus full-dose cyclosporine and mycophenolate in de novo renal transplant patients: a 2-year single-center experience.
    Santos SM; Carlos CM; Cabanayan-Casasola CB; Danguilan RA
    Transplant Proc; 2012 Jan; 44(1):154-60. PubMed ID: 22310603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical experience with Certican (everolimus) in de novo heart transplant patients at the Deutsches Herzzentrum Berlin.
    Lehmkuhl H; Hetzer R
    J Heart Lung Transplant; 2005 Apr; 24(4 Suppl):S201-5; discussion S210-1. PubMed ID: 15774323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Everolimus with reduced calcineurin inhibitor in thoracic transplant recipients with renal dysfunction: a multicenter, randomized trial.
    Gullestad L; Iversen M; Mortensen SA; Eiskjaer H; Riise GC; Mared L; Bjørtuft O; Ekmehag B; Jansson K; Simonsen S; Gude E; Rundqvist B; Fagertun HE; Solbu D; Bergh CH
    Transplantation; 2010 Apr; 89(7):864-72. PubMed ID: 20061999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Everolimus in clinical practice--renal transplantation.
    Pascual J
    Nephrol Dial Transplant; 2006 Jul; 21 Suppl 3():iii18-23. PubMed ID: 16815852
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of clinical events with everolimus exposure in kidney transplant patients receiving reduced cyclosporine.
    Shihab FS; Cibrik D; Chan L; Kim YS; Carmellini M; Walker R; Zibari G; Pattison J; Cornu-Artis C; Wang Z; Tedesco-Silva H
    Clin Transplant; 2013; 27(2):217-26. PubMed ID: 23230975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of sirolimus and everolimus in heart transplant patients: a retrospective analysis.
    Baur B; Oroszlan M; Hess O; Carrel T; Mohacsi P
    Transplant Proc; 2011 Jun; 43(5):1853-61. PubMed ID: 21693289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improvement of renal function after the switch from a calcineurin inhibitor to everolimus in liver transplant recipients with chronic renal dysfunction.
    Castroagudín JF; Molina E; Romero R; Otero E; Tomé S; Varo E
    Liver Transpl; 2009 Dec; 15(12):1792-7. PubMed ID: 19938140
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Everolimus: a proliferation signal inhibitor with clinical applications in organ transplantation, oncology, and cardiology.
    Gabardi S; Baroletti SA
    Pharmacotherapy; 2010 Oct; 30(10):1044-56. PubMed ID: 20874042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Calcineurin inhibitor-free immunosuppression using everolimus (Certican) in maintenance heart transplant recipients: 6 months' follow-up.
    Rothenburger M; Teerling E; Bruch C; Lehmkuhl H; Suwelack B; Bara C; Wichter T; Hinder F; Schmid C; Stypmann J
    J Heart Lung Transplant; 2007 Mar; 26(3):250-7. PubMed ID: 17346627
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Everolimus: a guide to its use in liver transplantation.
    Keating GM; Lyseng-Williamson KA
    BioDrugs; 2013 Aug; 27(4):407-11. PubMed ID: 23696253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Affects of immunosuppression on circulating dendritic cells: an adjunct to therapeutic drug monitoring after heart transplantation.
    Barten MJ; Garbade J; Bittner HB; Fiedler M; Dhein S; Thiery J; Mohr FW; Gummert JF
    Int Immunopharmacol; 2006 Dec; 6(13-14):2011-7. PubMed ID: 17161355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.